The DOI matches its Crossref record; 59 of the 60 references it cites were found in a registry or an index.
Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation.
Open accessAbstract
Apolipoprotein (apo) E and the two B apolipoproteins, apoB48 and apoB100, are important proteins in human lipoprotein metabolism. Commonly occurring polymorphisms in the genes for apoE and apoB result in amino acid substitutions that produce readily detectable phenotypic differences in these proteins. We studied changes in apoE and apoB phenotypes before and after liver transplantation to gain new insights into apolipoprotein physiology. In all 29 patients that we studied, the postoperative serum apoE phenotype of the recipient, as assessed by isoelectric focusing, converted virtually completely to that of the donor, providing evidence that greater than 90% of the apoE in the plasma is synthesized by the liver. In contrast, the cerebrospinal fluid apoE phenotype did not change to the donor's phenotype after liver transplantation, indicating that most of the apoE in CSF cannot be derived from the plasma pool and therefore must be synthesized locally. The apoB100 phenotype (assessed with immunoassays using monoclonal antibody MB19, an antibody that detects a two-allele polymorphism in apoB) invariably converted to the phenotype of the donor. In four normolipidemic patients, we determined the MB19 phenotype of both the apoB100 and apoB48 in the "chylomicron fraction" isolated from plasma 3 h after a fat-rich meal. Interestingly, the apoB100 in the chylomicron fraction invariably had the phenotype of the donor, indicating that the vast majority of the large, triglyceride-rich apoB100-containing lipoproteins that appear in the plasma after a fat-rich meal are actually VLDL of hepatic origin. The MB19 phenotype of the apoB48 in the plasma chylomicron fraction did not change after liver transplantation, indicating that almost all of the apoB48 in plasma chylomicrons is derived from the intestine. These results were consistent with our immunocytochemical studies on intestinal biopsy specimens of organ donors; using apoB-specific monoclonal antibodies, we found evidence for apoB48, but not apoB100, in donor intestinal biopsy specimens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ApoE found in the periphery and the central nervous system (CNS) are independent of each other and produced from different sources [3].”
From In Vivo Human Apolipoprotein E Isoform Fractional Turnover Rates in the CNS (2012) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A limited blood brain barrier permeability to circulating lipidpoor apoE2, apoE3, and apoE4 supports that apoE in blood and brain are regulated independently [72,107,108].”
From Plasma levels of apolipoprotein E, APOE genotype and risk of dementia and ischemic heart disease: A review (2016) · cites this paper as [72]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ApoE in the brain and CSF is synthesized within the central nervous system and is not derived from other organs.13”
From ApoE is Secreted as a Lipid Nanoparticle by Mammalian Cells: Implications for Alzheimer’s Disease Pathogenesis (2025) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“APOE circulating in the blood is predominantly produced by the liver; however, the BBB keeps this pool of peripheral APOE separated from that produced in the CNS181,182.”
From Multifaceted roles of APOE in Alzheimer disease (2024) · cites this paper as [182]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, human liver transplant studies show that systemic ApoE does not enter into the central nervous system due to the blood brain barrier and knockout of hepatic ApoE does not have an effect on Aβ pathology in the APP/PS1-21 mouse model of Aβ amyloidosis [15, 16].”
From ApoE lipoproteins in the central nervous system under homeostasis and role in Alzheimer’s disease and related disorders (2026) · cites this paper as [16]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“suggesting that apoE in blood and brain are regulated independently.61,63”
From Plasma levels of apolipoprotein E, APOE genotype, and all-cause and cause-specific mortality in 105 949 individuals from a white general population cohort (2019) · cites this paper as [61]
The cited source says what the claim attributes to it.
In the citing paper
“Human liver transplantation studies clearly showed that apoE in the peripheral circulation and in the central nervous system originates from two separate compartments.61”
From Plasma levels of apolipoprotein E, APOE genotype, and all-cause and cause-specific mortality in 105 949 individuals from a white general population cohort (2019) · cites this paper as [61]
The cited source says what the claim attributes to it.
In the citing paper
“About 90% of serum apoE is made in the liver ( 10 ) and the remainder is produced by macrophages ( 11 ).”
From Macrophage-derived apoESendai suppresses atherosclerosis while causing lipoprotein glomerulopathy in hyperlipidemic mice (2014) · cites this paper as [10]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“However, human liver transplant studies show that systemic ApoE does not enter into the central nervous system due to the blood brain barrier and knockout of hepatic ApoE does not have an effect on Aβ pathology in the APP/PS1-21 mouse model of Aβ amyloidosis [15, 16].”
From ApoE lipoproteins in the central nervous system under homeostasis and role in Alzheimer’s disease and related disorders (2026) · cites this paper as [16]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENT
Lowry, O. H., Rosebrough, N., Farr, A. L., & Randall, R. (1951) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52451-6 · Cited by 316,394
Havel, R. J., Eder, H. A., & Bragdon, J. H. (1955) · Journal of Clinical Investigation · doi:10.1172/jci103182 · Cited by 8,737
The Metabolic Basis of Inherited Disease.
(1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-3-503_7 · Cited by 7,807
The Metabolic Basis of Inherited Disease
(1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-5-389_2 · Cited by 3,990
Basic Methods in Molecular Biology
(1986) · Elsevier eBooks · doi:10.1016/b978-0-444-01082-7.x5001-2 · Cited by 3,163
A novel form of tissue-specific RNA processing produces apolipoprotein-B48 in intestine
Powell, L. M., Wallis, S. C., Pease, R. J., Edwards, Y. H., Knott, T. J., & Scott, J. (1987) · Cell · doi:10.1016/0092-8674(87)90510-1 · Cited by 1,045
Basic methods in molecular biology
Potter, H. (1987) · Trends in Neurosciences · doi:10.1016/0166-2236(87)90137-8 · Cited by 832
Boyles, J. K., Pitas, R. E., Wilson, E., Mahley, R. W., & Taylor, J. M. (1985) · Journal of Clinical Investigation · doi:10.1172/jci112130 · Cited by 829
Self-citationApolipoprotein B-48 Is the Product of a Messenger RNA with an Organ-Specific In-Frame Stop Codon
Chen, S. H., Habib, G. M., Yang, C., Gu, Z.-W., Lee, B. R., Weng, S. A., Silberman, S. R., Cai, S.-J., Deslypère, J. P., Rosseneu, M., et al. (1987) · Science · doi:10.1126/science.3659919 · Cited by 756
Pitas, R. E., Boyles, J. K., Lee, S. H., Hui, D., & Weisgraber, K. H. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47945-8 · Cited by 714
Self-citation
Flagged first, then by citations
1 of the 60 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Butler, R. 1990. Advances in Forensic Science. Vol. 3. DNA and Other Polymorphisms in Forensic Sciences.
Cited by
Sorted by citations
APOE and Alzheimer’s disease: Advances in genetics, pathophysiology, and therapeutic approaches
Serrano-Pozo, A., Das, S., & Hyman, B. T. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30412-9 · Cited by 1,037
Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders
Mahley, R. W. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1427-y · Cited by 837
apoE isoform–specific disruption of amyloid β peptide clearance from mouse brain
Deane, R., Sagare, A., Hamm, K., Parisi, M., Lane, S., Finn, M. B., Holtzman, D. M., & Zlokovic, B. V. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36663 · Cited by 771
ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies
Raulin, A.-C., Doss, S. V., Trottier, Z. A., Ikezu, T. C., Bu, G., & Liu, C.-C. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00574-4 · Cited by 756
Cholesterol metabolism and homeostasis in the brain
Zhang, J., & Liu, Q. (2015) · Protein & Cell · doi:10.1007/s13238-014-0131-3 · Cited by 686
A Quarter Century of APOE and Alzheimer’s Disease: Progress to Date and the Path Forward
Belloy, M. E., Napolioni, V., & Greicius, M. D. (2019) · Neuron · doi:10.1016/j.neuron.2019.01.056 · Cited by 570
Central Nervous System Lipoproteins: ApoE and Regulation of Cholesterol Metabolism
Mahley, R. W. (2016) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.116.307023 · Cited by 516
Cholesterol metabolism in neurons and astrocytes
Pfrieger, F. W., & Ungerer, N. (2011) · Progress in Lipid Research · doi:10.1016/j.plipres.2011.06.002 · Cited by 500
Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation
Linton, M. F., Atkinson, J. B., & Fazio, S. (1995) · Science · doi:10.1126/science.7863332 · Cited by 478
Self-citationWahrle, S. E., Jiang, H., Parsadanian, M., Legleiter, J., Han, X., Fryer, J. D., Kowalewski, T., & Holtzman, D. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407963200 · Cited by 474
Deficiency of ABCA1 Impairs Apolipoprotein E Metabolism in Brain
Hirsch-Reinshagen, V., Zhou, S., Burgess, B. L., Bernier, L., McIsaac, S. A., Chan, J. Y., Tansley, G. H., Cohn, J. S., Hayden, M. R., & Wellington, C. L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407962200 · Cited by 385
Apolipoprotein E, Receptors, and Modulation of Alzheimer’s Disease
Zhao, N., Liu, C.-C., Qiao, W., & Bu, G. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.03.003 · Cited by 370
Buttini, M., Orth, M., Bellosta, S., Akeefe, H., Pitas, R. E., Wyss‐Coray, T., Mucke, L., & Mahley, R. W. (1999) · Journal of Neuroscience · doi:10.1523/jneurosci.19-12-04867.1999 · Cited by 363
Holtzman, D. M., Bales, K. R., Wu, S., Bhat, P., Parsadanian, M., Fagan, A. M., Chang, L. K., Sun, Y., & Paul, S. M. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6179 · Cited by 349
Cholesterol: its regulation and role in central nervous system disorders
Orth, M., & Bellosta, S. (2012) · Cholesterol · doi:10.1155/2012/292598 · Cited by 339
Apolipoprotein E: From lipid transport to neurobiology
Hauser, P. S., Narayanaswami, V., & Ryan, R. O. (2011) · Progress in Lipid Research · doi:10.1016/j.plipres.2010.09.001 · Cited by 320
Bellosta, S., Nathan, B. P., Orth, M., Dong, L.-M., Mahley, R. W., & Pitas, R. E. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.45.27063 · Cited by 313
APOE2: protective mechanism and therapeutic implications for Alzheimer’s disease
Li, Z., Shue, F., Zhao, N., Shinohara, M., & Bu, G. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00413-4 · Cited by 306
Characterization of four lipoprotein classes in human cerebrospinal fluid
Koch, S., Donarski, N., Goetze, K., Kreckel, M., Stuerenburg, H.-J., Buhmann, C., & Beisiegel, U. (2001) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)31605-9 · Cited by 298
Increased atherosclerosis in mice reconstituted with apolipoprotein E null macrophages
Fazio, S., Babaev, V. R., Murray, A. B., Hasty, A. H., Carter, K. J., Gleaves, L. A., Atkinson, J. B., & Linton, M. F. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4647 · Cited by 295
Self-citationApolipoprotein E in lipid metabolism and neurodegenerative disease
Yang, L. G., March, Z. M., Stephenson, R. A., & Narayan, P. S. (2023) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2023.05.002 · Cited by 286
Nascent astrocyte particles differ from lipoproteins in CSF
LaDu, M. J., Gilligan, S. M., Lukens, J. R., Cabana, V. G., Reardon, C. A., Van Eldik, L. J., & Holtzman, D. M. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.70052070.x · Cited by 285
Bellosta, S., Mahley, R. W., Sanan, D. A., Murata, J., Newland, D. L., Taylor, J. M., & Pitas, R. E. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118271 · Cited by 284
Fernández-Calle, R., Konings, S. C., Frontiñán-Rubio, J., García-Revilla, J., Camprubí-Ferrer, L., Svensson, M., Martinson, I., Boza-Serrano, A., Venero, J. L., Nielsen, H. M., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00566-4 · Cited by 278
Lipid Processing in the Brain: A Key Regulator of Systemic Metabolism
Bruce, K. D., Zsombok, A., & Eckel, R. H. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00060 · Cited by 279
APOE mediated neuroinflammation and neurodegeneration in Alzheimer’s disease
Parhizkar, S., & Holtzman, D. M. (2022) · Seminars in Immunology · doi:10.1016/j.smim.2022.101594 · Cited by 255
Achariyar, T. M., Li, B., Peng, W., Verghese, P. B., Shi, Y., McConnell, E., Benraiss, A., Kasper, T., Song, W., Takano, T., et al. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0138-8 · Cited by 256
HDL and cholesterol handling in the brain
Vitali, C., Wellington, C. L., & Calabresi, L. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu148 · Cited by 254
Cohn, J. S., Johnson, E. J., Millar, J. S., Cohn, S. D., Milne, R. W., Marcel, Y. L., Russell, R. M., & Schaefer, E. J. (1993) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)35345-1 · Cited by 248
Linton, M. F., Farese, R. V., Chiesa, G., Grass, D., Chin, P., Hammer, R. E., Hobbs, H. H., & Young, S. G. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116927 · Cited by 246
Self-citationCholesterol metabolism and transport in the pathogenesis of Alzheimer’s disease
Martins, I. J., Berger, T. R., Sharman, M. J., Verdile, G., Fuller, S. J., & Martins, R. N. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06408.x · Cited by 237
Simonet, W. S., Bucay, N., Lauer, S., & Taylor, J. M. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53085-4 · Cited by 213
Sun, Y., Wu, S., Bu, G., Onifade, M. K., Patel, S. N., LaDu, M. J., Fagan, A. M., & Holtzman, D. M. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-09-03261.1998 · Cited by 213
Downregulation of microglial activation by apolipoprotein E and apoE-mimetic peptides
Laskowitz, D. T., Thekdi, A. D., Thekdi, S. D., Han, S. K. D., Myers, J. K., Pizzo, S. V., & Bennett, E. R. (2001) · Experimental Neurology · doi:10.1006/exnr.2001.7541 · Cited by 206
Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease
Cruchaga, C., Kauwe, J. S. K., Nowotny, P., Bales, K., Pickering, E. H., Mayo, K., Bertelsen, S., Hinrichs, A., Fagan, A. M., Holtzman, D. M., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds296 · Cited by 207
Boisvert, W. A., Spangenberg, J., & Curtiss, L. K. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118098 · Cited by 207
Lipoproteins in the Central Nervous System
LADU, M. J., REARDON, C., VAN ELDIK, L., FAGAN, A. M., BU, G., HOLTZMAN, D., & GETZ, G. S. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06365.x · Cited by 167
Apolipoproteins in the brain: implications for neurological and psychiatric disorders
Elliott, D. A., Weickert, C. S., & Garner, B. (2010) · Clinical Lipidology · doi:10.2217/clp.10.37 · Cited by 194
APOE4 derived from astrocytes leads to blood–brain barrier impairment
Jackson, R. J., Meltzer, J. C., Nguyen, H., Commins, C., Bennett, R. E., Hudry, E., & Hyman, B. T. (2022) · Brain · doi:10.1093/brain/awab478 · Cited by 205
Multifaceted roles of APOE in Alzheimer disease
Jackson, R. J., Hyman, B. T., & Serrano-Pozo, A. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-00988-2 · Cited by 193
Cholesterol in myelin biogenesis and hypomyelinating disorders
Saher, G., & Stumpf, S. K. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2015.02.010 · Cited by 192
Lynch, J., Morgan, D., Mance, J., Matthew, W. D., & Laskowitz, D. T. (2001) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(00)00459-8 · Cited by 189
Increased Risk of Late Posttraumatic Seizures Associated With Inheritance of APOE ϵ4 Allele
Diaz-Arrastia, R. R., Gong, Y., Fair, S., Scott, K. D., García, M. C., Carlile, M. C., Agostini, M. A., & Ness, P. C. V. (2003) · Archives of Neurology · doi:10.1001/archneur.60.6.818 · Cited by 186
HDL and cognition in neurodegenerative disorders
Hottman, D. A., Chernick, D., Cheng, S., Wang, Z., & Li, L. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.07.015 · Cited by 188
DeMattos, R. B., Brendza, R. P., Heuser, J. E., Kierson, M., Cirrito, J. R., Fryer, J., Sullivan, P. M., Fagan, A. M., Han, X., & Holtzman, D. M. (2001) · Neurochemistry International · doi:10.1016/s0197-0186(01)00049-3 · Cited by 180
Formation and function of apolipoprotein E-containing lipoproteins in the nervous system
Vance, J. E., & Hayashi, H. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.02.007 · Cited by 155
Chiesa, G., Hobbs, H. H., Koschinsky, M. L., Lawn, R. M., Maika, S. D., & Hammer, R. E. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)35775-2 · Cited by 179
Therapeutic approaches targeting Apolipoprotein E function in Alzheimer’s disease
Williams, T., Borchelt, D., & Chakrabarty, P. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-0358-9 · Cited by 172
Horsburgh, K. J., McCarron, M. O., White, F., & Nicoll, J. A. R. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00097-x · Cited by 169
Cholesterol metabolism in the brain and its association with Parkinson’s disease.
Jin, U., Park, S. J., & Park, S. M. (2019) · Experimental Neurobiology · doi:10.5607/en.2019.28.5.554 · Cited by 169
Liu, C.-C., Zhao, J., Fu, Y., Inoue, Y., Ren, Y., Chen, Y., Doss, S. V., Shue, F., Jeevaratnam, S., Bastea, L., et al. (2022) · Nature Neuroscience · doi:10.1038/s41593-022-01127-0 · Cited by 168
Martínez-Morillo, E., Hansson, O., Atagi, Y., Bu, G., Minthon, L., Diamandis, E. P., & Nielsen, H. M. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1266-2 · Cited by 168
Tai, L. M., Ghura, S., Koster, K. P., Liakaite, V., Maienschein‐Cline, M., Kanabar, P., Collins, N., Ben‐Aissa, M., Lei, A. Z., Bahroos, N., et al. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13072 · Cited by 165
Apolipoprotein E and cholesterol in aging and disease in the brain
de Chaves, E. P., Narayanaswami, V., Christoffersen, C., & Nielsen, L. B. (2008) · Future Lipidology · doi:10.2217/17460875.3.5.505 · Cited by 164
Liang, Y., Lin, S., Beyer, T. P., Zhang, Y., Wu, X., Bales, K. R., DeMattos, R. B., May, P. C., Li, S. D., Jiang, X., et al. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02183.x · Cited by 160
Plasma levels of apolipoprotein Eand risk of dementia in the general population
Rasmussen, K. L., Tybjærg‐Hansen, A., Nordestgaard, B. G., & Frikke‐Schmidt, R. (2015) · Annals of Neurology · doi:10.1002/ana.24326 · Cited by 156
Beyond the CNS: The many peripheral roles of APOE
Martínez-Martínez, A. B., Torres-Perez, E., Devanney, N., Del Moral, R., Johnson, L. A., & Arbones-Mainar, J. M. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104809 · Cited by 149
Martel, C. L., Mackic, J. B., Matsubara, E., Governale, S., Miguel, C., Miao, W., McComb, J. G., Frangione, B., Ghiso, J., & Zlokovic, B. V. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69051995.x · Cited by 149
Apolipoprotein E and Alzheimer Disease: An Update on Genetic and Functional Analyses
Saunders, A. M. (2000) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/59.9.751 · Cited by 147
Holtzman, D. M. (2001) · Journal of Molecular Neuroscience · doi:10.1385/jmn:17:2:147 · Cited by 143
Beffert, U., Cohn, J. S., Petit-Turcotte, C., Tremblay, M., Aumont, N., Ramassamy, C., Davignon, J., & Poirier, J. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01894-6 · Cited by 142
Zloković, B. V. (1996) · Life Sciences · doi:10.1016/0024-3205(96)00310-4 · Cited by 139
Fryer, J. D., DeMattos, R. B., McCormick, L. M., O'Dell, M. A., Spinner, M. L., Bales, K. R., Paul, S. M., Sullivan, P. M., Parsadanian, M., Bu, G., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m502143200 · Cited by 139
Genetic heterogeneity of apolipoprotein E and its influence on plasma lipid and lipoprotein levels
de Knijff, P., van den Maagdenberg, A. M. J. M., Frants, R. R., & Havekes, L. M. (1994) · Human Mutation · doi:10.1002/humu.1380040303 · Cited by 137
Morikawa, M., Fryer, J. D., Sullivan, P. M., Christopher, E. A., Wahrle, S. E., DeMattos, R. B., O'Dell, M. A., Fagan, A. M., Lashuel, H. A., Walz, T., et al. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.11.005 · Cited by 126
Apolipoproteins and aging: emerging mechanisms
Smith, J. D. (2002) · Ageing Research Reviews · doi:10.1016/s1568-1637(02)00005-3 · Cited by 133
祐幸, 齋., Wang, H., Mace, B. E., Leinenweber, S., Warner, D. S., Bennett, E. R., Vitek, M. P., McKenna, S., & Laskowitz, D. T. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2004.11.014 · Cited by 128
Rasmussen, K. L. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.10.037 · Cited by 125
Lehtim�ki, T., Pirttil�, T., Mehta, P., Wisniewski, H., Frey, H., & Nikkari, T. (1995) · Human Genetics · doi:10.1007/bf00225071 · Cited by 125
APOE3ch alters microglial response and suppresses Aβ-induced tau seeding and spread
Chen, Y., Song, S., Parhizkar, S., Lord, J., Zhu, Y., Strickland, M. R., Wang, C., Park, J., Tabor, G. T., Jiang, H., et al. (2024) · Cell · doi:10.1016/j.cell.2023.11.029 · Cited by 120
Shih, S.-J., Allan, C., Grehan, S., Tse, E., Moran, C., & Taylor, J. M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m005468200 · Cited by 112
The emergence of mouse models of atherosclerosis and their relevance to clinical research
Smith, J. D., & Breslow, J. L. (1997) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1997.00197.x · Cited by 108
Potential biomarkers in psychiatry: focus on the cholesterol system
Woods, A. G., Sokolowska, I., Taurines, R., Gerlach, M., Dudley, E., Thome, J., & Darie, C. C. (2012) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2012.01543.x · Cited by 106
Trafficking of Cholesterol from Cell Bodies to Distal Axons in Niemann Pick C1-deficient Neurons
Karten, B., Vance, D. E., Campenot, R. B., & Vance, J. E. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m205406200 · Cited by 106
Allan, C. M., Taylor, S., & Taylor, J. M. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.46.29113 · Cited by 106
Brodbeck, J., McGuire, J., Liu, Z., Meyer-Franke, A., Balestra, M. E., Jeong, D.-E., Pleiss, M., McComas, C., Hess, F., Witter, D., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.217380 · Cited by 113
High-Density Lipoproteins and Cerebrovascular Integrity in Alzheimer’s Disease
Stukas, S. K., Robert, J., & Wellington, C. L. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.01.003 · Cited by 101
Zhang, H., Wu, J., & Zhu, J. (2010) · Journal of Immunology Research · doi:10.1155/2010/186813 · Cited by 99
Laskowitz, D. T., McKenna, S., Song, P., Wang, H., Durham, L., Yeung, N., Christensen, D. J., & Vitek, M. P. (2007) · Journal of Neurotrauma · doi:10.1089/neu.2006.0192 · Cited by 99
Interactions of Lipids, Lipoproteins, and Apolipoproteins with the Blood-Brain Barrier
Rhea, E. M., & Banks, W. A. (2021) · Pharmaceutical Research · doi:10.1007/s11095-021-03098-6 · Cited by 104
Roles of ApoE4 on the Pathogenesis in Alzheimer’s Disease and the Potential Therapeutic Approaches
Sun, Y.-Y., Wang, Z., & Huang, H. (2023) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-023-01365-1 · Cited by 102
The role of apolipoprotein E in Alzheimer’s disease: pharmacogenomic target selection
Saunders, A. M., Trowers, M. K., Shimkets, R. A., Blakemore, S., Crowther, D., Mansfield, T. A., Wallace, D. M., Strittmatter, W. J., & Roses, A. D. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(00)00035-1 · Cited by 92
Laskowitz, D. T., Song, P., Wang, H., Mace, B. E., Sullivan, P. M., Vitek, M. P., & Dawson, H. N. (2010) · Journal of Neurotrauma · doi:10.1089/neu.2010.1396 · Cited by 91
Linton, M. F., Hasty, A. H., Babaev, V. R., & Fazio, S. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2181 · Cited by 100
Self-citationLipoproteins in the Central Nervous System: From Biology to Pathobiology
Raulin, A.-C., Martens, Y. A., & Bu, G. (2022) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-032620-104801 · Cited by 89
Sphingolipids in Alzheimer's disease, how can we target them?
Crivelli, S. M., Giovagnoni, C., Visseren, L., Scheithauer, A.-L., de Wit, N. M., den Hoedt, S., Losen, M. H., Mulder, M. T., Walter, J., de Vries, H. E., et al. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.12.003 · Cited by 88
Rasmussen, K. L., Tybjærg-Hansen, A., Nordestgaard, B. G., & Frikke-Schmidt, R. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz402 · Cited by 86
Bekris, L. M., Millard, S. P., Galloway, N. M., Vuletic, S., Albers, J. J., Li, G., Galasko, D. R., DeCarli, C., Farlow, M. R., Clark, C. M., et al. (2008) · Journal of Alzheimer's Disease · doi:10.3233/jad-2008-13303 · Cited by 85
Lefèvre, M., Felmlee, D. J., Parnot, M., Baumert, T. F., & Schuster, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095550 · Cited by 99
Fan, J., Ji, Z. S., Huang, Y., de Silva, H., Sanan, D. A., Mahley, R. W., Innerarity, T. L., & Taylor, J. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1599 · Cited by 83
Gao, J., Wang, H., Sheng, H., Lynch, J., Warner, D. S., Durham, L., Vitek, M. P., & Laskowitz, D. T. (2006) · Neurocritical Care · doi:10.1385/ncc:4:1:025 · Cited by 82
Laskowitz, D. T., Fillit, H. M., Yeung, N., Toku, K., & Vitek, M. P. (2006) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2006.00680.x · Cited by 82
Transendothelial transport of lipoproteins
Jang, E., Robert, J., Rohrer, L., von Eckardstein, A., & Lee, W. L. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.09.020 · Cited by 85
Central Nervous System Remyelination: Roles of Glia and Innate Immune Cells
Baaklini, C. S., Rawji, K. S., Duncan, G. J., Ho, M. F. S., & Plemel, J. R. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00225 · Cited by 88
Lipid Metabolism and Glial Lipoproteins in the Central Nervous System
Hayashi, H. (2011) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.34.453 · Cited by 80
Apolipoprotein E and ALzheimer's Disease: The Tip of the Susceptibility Iceberg
Roses, A. D. (1998) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1998.tb10653.x · Cited by 77
Raffaı̈, R. L., & Weisgraber, K. H. (2003) · Journal of Lipid Research · doi:10.1194/jlr.r300007-jlr200 · Cited by 76
Monnot, M. J., Babin, P. J., Poleo, G. A., Andre, M., Laforest, L., Ballagny, C., & Akimenko, M. (1999) · Developmental Dynamics · doi:10.1002/(sici)1097-0177(199903)214:3 · Cited by 77
Insulin Resistance in Peripheral Tissues and the Brain: A Tale of Two Sites
Rhea, E. M., Banks, W. A., & Raber, J. (2022) · Biomedicines · doi:10.3390/biomedicines10071582 · Cited by 76
Rasmussen, K. L., Tybjærg‐Hansen, A., Nordestgaard, B. G., & Frikke‐Schmidt, R. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.05.006 · Cited by 75
Metadata
- Authors
- Linton, M. F., Gish, R., Hubl, S. T., Bütler, E., Esquivel, C., Bry, W. I., Boyles, J. K., Wardell, M. R., & Young, S. G.
- Affiliations
- University of California, San Francisco (US)
- Gladstone Institutes (US)
- Venue
- Journal of Clinical Investigation
- Published
- 1991-07-01
- Volume
- 88
- Issue
- 1
- Pages
- 270-281
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2115309238
- Cited by
- 367
- References
- 60
- Citations by year
- 2026: 8 · 2025: 20 · 2024: 12 · 2023: 20 · 2022: 18 · 2021: 11 · 2020: 25 · 2019: 13 · 2018: 4 · 2017: 9 · 2016: 8 · 2015: 11 · 2014: 13 · 2013: 10 · 2012: 11
- FWCI
- 4.40
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Heart Association
- National Institutes of Health
- National Heart, Lung, and Blood Institute (HL-41633, P01HL041633, HL 01672)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- apolipoprotein E, apolipoprotein B, apolipoprotein B-48, apolipoprotein B-100, liver transplantation, chylomicrons, VLDL, lipoprotein metabolism
- MeSH terms
- Adult, Apolipoproteins B, Apolipoproteins E, Chylomicrons, Glycosylation, Humans, Immunohistochemistry, Lipoproteins, VLDL, Middle Aged, Phenotype, Liver Transplantation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
